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Abstract
Purpose: Epithelial ovarian cancer is the most common ovarian cancer and has lifethreatening implications. Despite the progress in surgical and therapeuticstrategies, resistance to chemotherapy is still a major concern. Chemotherapeuticagents cause cytotoxicity, primarily by the induction of apoptosis. The status of p53is a key factor in determining the efficacy of apoptotic signaling. p53 is the mostcommonly mutated tumor suppressor gene in ovarian cancer. Metformin (anantidiabetic drug) has shown putative effects in many solid tumors. Hence weaimed to study the role of metformin in p53 mutated cancer cells. Methods: SKOV3and OAW42 ovarian cancer cell line were used. The cancer cells were treated withmetformin. MTT, Flow cytometry and Western blotting were used to characterizethe effects of the different treatments. Results: Metformin treatment leads to cellcycle arrest in the G0/G1, S and G2/M phase of the cell cycle in SKOV3 and OAW42respectively. Moreover, there was upregulation of Bax and downregulation of Bcl-2protein and increased apoptosis in SKOV3 and OAW42 ovarian cancer cells.
Conclusion: These findings support the potential of metformin to be used aschemoadjuvant and reflects its ability to sensitize cancer cells to apoptosisindependent of p53 status.
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1. IntroductionEpithelial Ovarian cancer is a lethal gynecological cancerbeing seventh most common cancer in world and fourthmost common cancer in India (GLOBOCAN 2012). Mostpatients diagnosed in advanced stages undergoremission after optimal surgical cytoreductive andplatinum/taxane based chemotherapy.1 Despite theadvent of new chemotherapies and molecular targetedtherapies, prognosis still remains poor and mostpatients with metastatic cancer succumb to theirdisease.2The major obstacle in the treatment of cancer isresistance to chemotherapy. Drug resistance eitheracquired or intrinsic often prevents tumor cells fromundergoing sufficient levels of programmed cell death orapoptosis leading to survival of cancer cells andtreatment failure.2,3 Hence identifying novel therapeuticstrategies or repositioning existing drugs that target keycomponents of the apoptotic machinery is needed toimprove patient survival. Metformin an antidiabeticdrug has shown promising anticancer effects in an array
of cancers like triple negative breast tumors4 prostate5,pancreas6, colon7 and gliomas.8Metformin is a commonly prescribed oral hypoglycemicagent for type 2 diabetes. The anticancer effects ofmetformin are associated with both direct (insulinindependent) and indirect (insulin dependent) actions.The indirect insulin dependent effects of metformin aremediated by reducing fasting blood glucose andinsulin9,10. Metformin plays a major role in its anticanceractivity by lowering insulin levels since insulin hasmitogenic and prosurvival effects and tumor cells oftenexpress high levels of the insulin receptor.
11,12,13 Whereas it exerts its direct, insulin independentaction through 5' adenosine monophosphate-activatedprotein kinase (AMPK) activation and decreasedmammalian target of rapamycin (mTOR) signaling andprotein synthesis in cancer cells. Moreoever, metforminis a cheap and widely available drug with minimal sideeffects like nausea, diarrhoea.14,15
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It has been reported that metformin treatmentsignificantly inhibited proliferation of diversechemoresponsive and resistant ovarian cancer cell lines,caused cell cycle arrest, decreased cyclin D1 andincreased p21 protein expression.16 Besides, metformininduced significant growth inhibition of OVCAR-3 andOVCAR-4 ovarian cancer cell lines in a time and dosedependent manner, increased cytotoxicity with cisplatinas compared to each agent alone17, induced apoptosis byactivating caspases 3/7, downregulating Bcl-2 andBcl-xL expression, upregulating Bax and Badexpression.18 Hence, we decided to study apoptoticpotential of metformin in ovarian cancer.Many tumor suppressor genes are implicated in thepathogenesis of ovarian cancer. These include the TP53gene which plays a major role in chemotherapyresistance and is associated with disease metastasizedbeyond the ovary.19,20 p53 is located on 17p13 whichencodes a nuclear phosphoprotein and is altered in 50%of cases of ovarian cancer.21,22 p53 expression is inducedin response to oncogene activation, hypoxia and DNAdamage and has multiple effects on gene expression. Itcauses transcriptional activation of p21, inhibitor ofdifferent cyclin/cyclin-dependent kinase complexesleading to cell cycle arrest. p53 protein also plays anintegral role in apoptosis by downregulation ofantiapoptotic genes and upregulation of proapoptoticgenes. In the present scenario, there are no effectivebiological markers that can be used to assess patientresponse to chemotherapy. Several differentoncomorphic mutations have been reported in literatureeach of which acts in a distinct manner and has adifferent effect on tumor progression and chemoresistance.23 Numerous studies have seen metformin’santicancer potential but not enough light has been shedon p53 status of the cell. There is a paucity of literaturedemonstrating the role of metformin in p53 mutatedovarian cancer lines. Hence, it is essential to understandthe altered pathways and design appropriate druginterventions to reduce morbidity and mortality of thislethal diseaseIn the OAW42 ovarian carcinoma cell line silentmutation (CGA-CCG substitution) is seen which codes forthe same amino acid (Arginine) as is present in wild type(wt) p53 protein24 whereas in SKOV3 cells p53 proteinexpression is absent due to single nucleotide deletion atposition 267 (codon 90). Hence SKOV3 is p53(-/-)ovarian cancer cell line. 21 It has been seen that p53inactivation and mutant p53 expression can endow thecells with additive growth and survival advantages suchas increased proliferation, evasion of apoptosis andchemo resistance.25,26 Thus we would like to seewhether metformin could induce apoptosis in this p53mutated (OAW42) and p53 null (SKOV3) ovarian cancercells so that it could be used for chemo adjuvant therapy.
2. Methods and Materials
2.1 Cells lines and treatmentThe ovarian cancer cell line SKOV3 and OAW42 wasobtained from NCCS, Pune, grown in Dulbecco'smodiﬁed Eagle's medium (DMEM) media supplementedwith heat inactivated 10% fetal bovine serum (FBS), 2mM glutamine, and 10μg/ml gentamicin. The cells wereroutinely passaged every 5–7 days. All cells weremaintained at 37 °C in a 5% CO2, 95% air atmosphereincubator. Assays were performed in medium containing1% FBS. Metformin was obtained from Sigma-Aldrich,USA (cat#D150959) and kept as a stock solution of 1 Min DMEM without serum.
2.2 Chemicals and antibodiesCell culture material was obtained from Sigma Aldrich(cat#D150959), USA. Anti-Bax, anti-Bcl2, anti-p53 andanti-β-actin antibodies, Alkaline phosphates-conjugatedanti-rabbit Ig G, anti-mouse Ig G, reagents werepurchased from Santa Cruz, USA.
2.3 Cell viability Assay (MTT assay)MTT assay was used to standardize the dose to be usedin the study. About, 5x104cells/well were plated in 96well culture plates and were treated with varyingconcentrations of metformin for 24, 48, 72 hours afterovernight incubation. It was followed by incubation ofcells with 100 µl of 5 mg/ml MTT for 4hrs at 370C.Formazan crystals once formed were dissolved inDimethyl sulfoxide (DMSO) and the absorbance wasmeasured at 570nm using 620nm as the referencewavelength in an ELISA reader. The standardized dosesof 15mM and 10mM metformin was used for treatmentof SKOV3 cells and OAW 42 for future experiments.
2.4 Flow cytometrySKOV3 and OAW42 ovarian cancer cells cells weretreated with standardized doses of 15mM metforminand 10mM respectively for 48 hrs. The adherent cellswere collected thereafter using trypsinEthylenediaminetetraacetic acid (EDTA) while floatingcells were collected by centrifugation. The cells weresubsequently washed twice with ice cold phosphatebuffered saline (PBS). After collection and washing, thecells were fixed in 70% ethanol. Subsequently for flowcytometric analysis the cells were then washed twicewith ice cold PBS and resuspended in propidium iodidebuffer (PBS, 0.1% Triton X-100, 0.1 mM EDTA, 0.05mg/ml ribonuclease A, and 50 mM propidium iodide) for30 minutes at room temperature. The cell cycle analysiswas then done by flow cytometry (BD Facs, USA) usingWin Mdi 2.9 software.27
2.5 Protein extraction and Western blot analysisThe ovarian cancer cells were lysed inRadioimmunoprecipitation assay buffer supplementedwith protease inhibitor cocktail tablets (G biosciences,USA). 60-100μg of protein lysates (estimated by
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Bradford method) were resolved electrophoretically on10%-15% denaturing SDS–polyacrylamide gels andtransferred to nitrocellulose membranes. 5% non-fatmilk was used for blocking following which membraneswere probed with the primary antibodies specific toBcl-2, Bax and β-actin. Immunoblotted proteins werevisualized using Alkaline Phosphatase conjugatedsecondary antibodies. Final detection was performedwith BCIP/NBT (5-bromo-4-chloro-3'-indolyphosphate/nitro-blue tetrazolium chloride) substrate (Promega,USA). Appropriate positive and negative controls wererun simultaneously. The bands were analyzed andquantitated using Alpha imager scanning densitometer(Alpha Innotech, USA) and its expression measured inRelative Units (RU). The density of the control was takenas 1 and the results of treatments were expressed inrelation to the control. The methods were done aspreviously described.27
2.6 Statistical analysisAll results are expressed as mean±SEM. For multiplecomparisons, data were analyzed by on-way ANOVA testfollowed by the post hoc Bonferroni test. P < 0.05 wasconsidered statistically significant.
3. Results
3.1 Metformin’s effect on cell proliferationThe cells were treated with different doses of metformin2.5, 5, 10, 15, 30, 50mM for duration of 24, 48 and 72hrs. The IC 50 (dose at which 50% of cells were viable)doses were established by doing a dose response curveand MTT assay (Figure 1). Morphological changescharacterized by membrane blebbing and formation ofapoptotic bodies were also observed. Metformininhibited growth of SKOV3. After 24 h, 30 mM of
metformin was able to significantly reduce the numberof viable cells whereas after 48 h, metformin at 15 mMshowed similar antiproliferative effect. At 48 h, IC50 ofmetformin was found to be 15 mM. Based on theseresults and those in several published reports, 15 mMmetformin was used in the following experiments.Similarly, in OAW42 cancer cells the IC50 at 48 hrs wasfound out to be 10mM.
3.2 Metformin affects cell cycle distributionThe effect of metformin on different phases of cell cyclewas analyzed by flow cytometry after treatment withstandardized doses of metformin. Metformin treatmentin SKOV3 resulted in increase of cells in the S phase ofthe cell cycle (29.8%) as compared to control (14.7%)whereas no significant difference was seen in theG0/G1-phase and G2–M phase cells compared to control.Similarly, metformin treatment in OAW42 resulted inincrease of cells in the G2–M phase of the cell cycle(36.8%) as compared to control (19.1%) whereas nosignificant difference was seen in the G1phase and theS-phase of cells compared to control (Figure 2a). Toassess whether the induction of apoptosis alsocontributed to metformin mediated inhibition of ovariancancer cell growth, the proportion of apoptotic cells wasmeasured. The mean percentage apoptosis in untreatedSKOV-3 and OAW42 control cells was 3.2 and 5.1%respectively. On treatment with standardized doses ofmetformin the mean percentage apoptosis was 38.06%and 32.2% (Figure 3) in SKOV- 3 and OAW42 cellsrespectively (Figure 2b). Our results demonstrate thatthe proportion of apoptotic cells was higher inmetformin treated cultures compared with that incontrols.
Figure 1: (left) Cell viability of SKOV3 and (right) OAW42 ovarian cancer cells treated with increasing doses of metformin for48 hours measured by MTT assay.
4 Patel et al.: Anticancer role of metformin in ovarian cancer International Journal of Cancer Therapy and Oncology
www.ijcto.org
© Patel et al. ISSN 2330-4049
Figure 2: (a) Bar diagram showing cell cycle distribution in control and treated SKOV-3(metformin 15mM) and OAW42(metformin 10mM) ovarian cancer cells for duration of 48 hours. The diagram represents mean of three independentexperiments ±SD. *P < 0.05 metformin treated versus control in SKOV-3 cancer cells, # P < 0.05 metformin treated versuscontrol OAW-42 cancer cells. (b) Representative experiment showing flow cytometric analysis for percentage apoptosis in (i)control SKOV3 (ii) treated SKOV3 and (iii) control OAW42 (iv) treated OAW42 ovarian cancer cells. In The horizontal margindrawn from Y axis to peak represents % of apoptotic cells. (c) Mean percentage apoptosis induced in control and treatedSKOV3 and OAW42 ovarian cancer cells as measured by flowcytometry. The diagram represents mean of three independentexperiments±SEM. **p < 0.01metformin versus control in SKOV3 cancer cells, ## p < 0.01 metformin versus control inOAW-42 ovarian cancer cells.
3.3 Effect of metformin on pro-survival and
anti-survival proteins of the Bcl-2 family in ovarian
cancer cells.The p53 status of the ovarian cancer cells were seen bywestern blotting in which SKOV3 showed no bandwhereas a distinct band was seen in OAW42 cancer cellsblots (Figure 3a). Similarly, we measured the levels ofproapoptotic and antiapoptotic proteins in the presenceof metformin. (Figure 3b). We found that the proteinexpression of Bcl-2 decreased by 1.5 fold and1.9 foldwith metformin in SKOV3 and OAW42 cells respectively.Similarly, protein expression of Bax was increased by 2.5and 2.2 fold in SKOV3 and OAW42 cells respectively(Figure 3c). These pro and anti-apoptotic proteinsregulate the permeability of outer mitochondrialmembrane and hence apoptosis. The protein expressionof Bax increases and Bcl-2 decreases in both SKOV3 andOAW42 irrespective of p53 status.
4. DiscussionOvarian cancer is a heterogeneous disease with interand intra-tumor heterogeneity and has a high mortalityrate. Despite advances in surgical and radiationtreatments, chemotherapy continues to be an importanttherapeutic option for different malignancies. Increasingchemo resistance and lack of successful new treatmentsevoke the need of comprehensive genomic analysis toidentify genetic abnormalities in ovarian tumors thatcould influence the pathophysiology of the disease andchemotherapeutic response.28,29,30 TP53 is the mostcommonly mutated gene in ovarian tumors. Theguardian of genome p53 normally protects againstcancer through protein-protein interactions, cell cyclearrest, apoptosis, autophagy and DNA damage repair.
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Figure 3: (a and b) Effect of metformin on the expression of anti-apoptotic and pro-apoptotic proteins (p53, Bcl-2, Bax and βActin) in SKOV3 and OAW42 ovarian cancer cells treated with 15 mM and 10 mM metformin for 48hrs respectively. Celllysates were subjected to Western blot, one representative blot out of three is shown. (c) Densitometric analysis of proteinexpression of Bcl-2 and Bax ovarian cancer cells in control and treated SKOV3 and OAW42 cells as measured by western blotanalysis. The diagram represents the mean of three independent experiments ± SEM. *P < 0.05, **P < 0.01 metformin versuscontrol in SKOV3 cancer cells, # P < 0.05, ## P < 0.01 metformin versus control in OAW42 cancer cells.There is also a need to develop new drugs or repositiondrugs for treating ovarian cancer. Originating from theFrench Lilac plant (Galega officinalis), metformin hasbeen able to reduce cancer risk31and mortality32 besidesinhibiting cancer cells in vitro and vivo. Hence, in thisstudy we sought to find whether metformin couldinduce apoptosis in ovarian cancer cells in p53 deficientand mutant cells. Metformin causes molecular activationof AMPK and inactivation of mTOR signaling in cancercells thereby exhibiting antiproliferative effect whereaschemotherapeutic drugs through activation of p53 yieldssimilar effects to metformin.33 In this study, we haveseen that metformin has antiproliferative effect andinduces cell cycle arrest in vitro. The effect of metforminon different stages of cell cycle was first studied tounderstand its anticancer potential.There were more cells in G0/G1 and S phase and G2Mphase cells in metformin treated SKOV3 and OAW42cultures respectively compared with those in controlcultures after 48hrs of treatment (Figure 2a) suggestingarrest of the cell cycle by metformin at two points. Itmay be due to p21 expression which can be induced byboth p53 dependent and independent mechanism. p21is a inhibitory regulator of the G1/S transition as well as
inhibitor of the cyclin dependent kinase (CDK1)/cyclin Bcomplex that causes G2/M arrest.34,35,36 p53 mutationsare one of the most common mutations and play anintegral role in pathogenesis and complexity of cancerimplicating the necessity of studying its role. SKOV3 cellline has a p53 null mutation and OAW42 silent mutation.In this study, we found that metformin induces cell cyclearrest in ovarian cancer cells both at G0/G1, S (inSKOV3) and G2/M (in OAW42) irrespective of p53status. Similarly, metformin induced cell cycle arrest inendometrial cancer cells in G1 and G2/M via ap53-independent pathway as reported by Takahashi et
al.37 Quieroz et al.38 have reported cell cycle arrest inG0/G1 phase in breast cancer cells. This difference incell cycle arrest may also be attributed to difference incell cycle specific conditions, incubation time anddosages of metformin or existing polymorphisms of themetformin transporter, OCT1 (organic cationtransporter).39 The role of OCT1 in metformin uptake byovarian cancer cells is under investigation.Further to study apoptotic potential of metformin, cellswere incubated with or without metformin (15 or 10mM) for 48 h, the proportion of apoptotic cells wasmeasured by flow cytometry. Metformin treatment led
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to increase in proportion of apoptotic cells in SKOV3 andOAW42 cultures compared with that in controls (Figure2b, 2c).We next sought to evaluate the effect of metformin onvarious pro and anti apoptotic proteins of the Bcl-2family. The exact molecular mechanism underlying theapoptotic response to metformin remains unclear.Metformin may induce Bcl-2 phosphorylation, whichmay be less capable of forming heterodimers with (theproapoptotic) Bax protein. This may lead to increasedformation of Bax:Bax homodimers, driving the celltowards apoptosis. Our results showed downregulationof antiapoptotic and upregulation of apoptotic proteinswith metformin treatment in both SKOV3 and OAW42cancer cells (Figure 3c). Metformin was able to induceapoptosis of SKOV3 and OAW42 ovarian cancer cells.These findings were in congruence with other studiesthat have reported apoptotic potential of metformin inprostate ovary, breast, colon, endometrial cancer cellsand esophageal squamous cell carcinomas15,18,40,41,42,43using different mechanisms..In our experiments we observed metformin irrespectiveof p53 status (OAW 42 cells and SKOV3 cell line) wasable to inhibit cell viability and modulate apoptoticproteins. However, additional studies are required forsuggesting that p53 independent apoptosis is likely thepredominant mechanism of cytotoxic action ofmetformin in SKOV3 cells. Besides, more studies arerequired to understand the molecular basis for thisdifferential response to enhance the effectiveness ofmetformin in the treatment of patients with malignantdisease.Moreover, it has been seen that metformin is selectivelytoxic to p53 deficient cells. In the presence of metformin,p53+/+ cells, but not p53-/-cells activated autophagy.Autophagy is a cellular survival pathway necessary tomaintain homeostasis in normal cells as well as in timesof metabolic stress with nutrient recycling.41 Metforminwas able to induce apoptosis in p53 -/- cancer cell lineSKOV3 comparable to OAW42. It may do so either bypreventing autophagy or inducing apoptosis in a p53independent pathway in SKOV3 cell line and p53dependent pathway in OAW42 cell line. Hence, furtherautophagic potential of metformin needs to be studied.TP53 plays an important role in complexity andheterogeneity in ovarian cancer pathogenesis,chemotherapeutics and prognosis. In the case ofmetformin, the crosstalk with autophagy, apoptosis,chemotherapeutic drugs induced signaling pathwaysmay result in direct interactions between these druginduced signaling systems at the level of AMPK.23Henceit is essential to study the effect of current and noveltreatment strategies like metformin in the light ofimportant and frequent mutations like p53.
5. ConclusionHence, in this study we have tried to demonstrate thatmetformin promotes the elimination of ovarian cancercells through regulation of apoptosis independent of p53status suggesting its future role as chemo adjuvant.These results are based on in vitro studies only andfurther in vivo studies are necessary.
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